Phenotypic characterization of human peripheral γδT-cell subsets in glioblastoma
- PMID: 35718749
- DOI: 10.1111/1348-0421.13016
Phenotypic characterization of human peripheral γδT-cell subsets in glioblastoma
Abstract
The antitumoral contribution of γδT cells depends on their activation and differentiation into effectors. This depends on different molecules and membrane receptors, which conditions their physiology. This study aimed to determine the phenotypic characteristics of γδT cells in glioblastoma (GBM) according to five layers of membrane receptors. Among ten GBM cases initially enrolled, five of them who had been confirmed by pathological examination and ten healthy controls underwent phenotyping of peripheral γδT cells by flow cytometry, using the following staining: αβTCR, γδTCR, CD3, CD4, CD8, CD16, CD25, CD27, CD28, CD45, CD45RA, CD56, NKG2D, CD272(BTLA), and CD279(PD-1). Compared with the controls, the results showed no significant change in the number of γδT cells. However, there was a decrease of double-negative (CD4- CD8- ) Tγδ cells and an increase of naive γδT cells, a lack of CD25 expression, a decrease of the expression of CD279, and a remarkable, but not significant, increase in the expression of the CD27 and CD28 costimulation markers. Among the γδT cell subsets, the number of Vδ2 decreased in glioblastoma and showed no significant difference in the expression of CD16, CD56, and NKG2D. In contrast, the number of Vδ1 increased in glioblastoma with overexpression of CD16, CD56, and NKG2D. Our results showed that γδT cells are prone to adopt a pro-inflammatory profile in the glioblastoma context, which suggests that they might be a potential tool to consider in T cell-based immunotherapy in glioblastoma. However, this requires additional investigation on a larger sample size.
Keywords: characterization; flow cytometry; glioblastomas; immunophenotyping; γδT cells.
© 2022 The Societies and John Wiley & Sons Australia, Ltd.
References
REFERENCES
-
- Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23:1985-96. https://doi.org/10.1158/1055-9965.EPI-14-0275
-
- Belghali MY, Ba-Mohamed S, Admou B, et al. Caractéristiques épidémiologiques, cliniques, thérapeutiques et évolutives des patients atteints de glioblastome cérébral: série de cas pris en charge au centre d'oncohématologie du Centre Hospitalier Universitaire Mohammed VI de Marrakech en 2016 et 2017. Pan Afr Med J. 2021;39:191. https://doi.org/10.11604/PAMJ.2021.39.191.28298
-
- Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:829-48. https://doi.org/10.1007/s00401-015-1432-1
-
- González-Tablas Pimenta M, Otero Á, Arandia Guzman DA, et al. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. Brain Pathol. 2021;31:365-80. https://doi.org/10.1111/bpa.12927
-
- Kabelitz D, Serrano R, Kouakanou L, et al. Cancer immunotherapy with γδ T cells: many paths ahead of us. Cell Mol Immunol. 2020;17:925-39. https://doi.org/10.1038/S41423-020-0504-X
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
